LABETALOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Labetalol, and when can generic versions of Labetalol launch?
Labetalol is a drug marketed by Amneal, Apothecon, Baxter Hlthcare Corp, Caplin, Gland Pharma Ltd, Hikma, Hospira, Onesource Specialty, Rising, Aiping Pharm Inc, Andas 5 Holding, Appco, Cadila Pharms Ltd, Epic Pharma Llc, Heritage Pharma, Hibrow Hlthcare, Macleods Pharms Ltd, Ph Health, Rubicon Research, Teva, Unichem, Watson Labs, and Zydus Pharms. and is included in twenty-eight NDAs.
The generic ingredient in LABETALOL is labetalol hydrochloride. There are fourteen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the labetalol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Labetalol
A generic version of LABETALOL was approved as labetalol hydrochloride by HERITAGE PHARMA on August 3rd, 1998.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LABETALOL?
- What are the global sales for LABETALOL?
- What is Average Wholesale Price for LABETALOL?
Summary for LABETALOL
| US Patents: | 0 |
| Applicants: | 23 |
| NDAs: | 28 |
| Drug Prices: | Drug price information for LABETALOL |
| Drug Sales Revenues: | Drug sales revenues for LABETALOL |
| DailyMed Link: | LABETALOL at DailyMed |



